-
Issue 3/2018 - Peking University Pioneer masters CO industrial exhaust gas recovery technology
Time of Update: 2022-11-14
Peking University pioneer masters CO industry exhaust gas recovery technology High-purity carbon monoxide (CO) is an important raw material for carbon-one chemical industry, and advanced separation, purification and purification technology is the key to obtaining economical and cheap CO sources.
-
Issue 3 2022 - Covestro acquires the remaining stake in Japan Fine Coatings Co., Ltd
Time of Update: 2022-11-12
Covestro acquires the remaining stake in Japan Fine Coatings Co.
Covestro acquires the remaining stake in Japan Fine Coatings Co.
Covestro acquires the remaining stake in Japan Fine Coatings Co.
Covestro acquires the remaining stake in Japan Fine Coatings Co.
-
Directly hit the hard core 3-layer in-mold combined with 27-layer co-extrusion distributor (core layer multiplication) in the CPP industry.
Time of Update: 2022-08-26
imagination is everythingIt's a preview of future lifeis your multidimensional competitiveness0101Focus on the presentFocus on the presentflexibility and adaptabilityflexibility and adaptability2021 m
-
PD-1 co-partner CIC:1/3 of non-small cell lung cancer patients reached complete remission
Time of Update: 2021-02-05
between May 15, 2015 and November 30, 2016, the study included 18 late-stage (mainly IV)NSCLCs, and patients voluntarily chose to receive PD-1-CIK cells (n) 7) Or treated with PD-1 (n s 11) alone, PD-L1 testing was performed on the tissues of 8 patients, 3 cases in the joint group were negative, 3 patients in the single drug group were negative in PD-L1, 2 were positive, of which 1 case was PD-L1≥50%.
-
Lancet Neurology: 1, 2, 3 and 6 spinal cord microcephaly disorder risk individuals to explicit co-assistance disorder (RISCA): a longitudinal cohort study
Time of Update: 2020-11-06
Our goal is to study the sensitivity of obvious health mutation carriers associated with SCA1, SCA2, SCA3, and SCA6 to co-dysfunction and to detect changes in these individuals by clinical and functional indicators.
-
S1P subject regulator Yunding Xinyao Pharmaceutical Co-technology New Drug Phase 3 Clinical Start Patient Recruitment.
Time of Update: 2020-10-15
On August 24th Everest Pharmaceuticals announced that it was recruiting patients in China for a randomized, placebo-controlled, double-blind, international multi-center Phase 3 clinical trial of etras
-
Two Phase 3 clinical trials of filgotinib, co-developed by Gilead and Galapagos, yieldpositive results
Time of Update: 2020-06-08
yesterday (October 11), Gilead Sciences and Galapagos (http:// announced the results of the 52-week trial in two phase 3 clinical trials (http:// in patients with severe rheumatoid arthritis (R
-
Borui biomedical Co., Ltd. received 3 GMP certificates
Time of Update: 2019-12-19
On December 18, Borui biopharmaceutical (Suzhou) Co., Ltd announced that its subsidiary Xintai Pharmaceutical (Suzhou) Co., Ltd had recently received three GMP certificates issued by Jiangsu Drug Admi